Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic ArthritisTRM Ltd, POB 493, Scarborough YO11 9FJ, England..
Univ Ghent, VIB UGent Ctr Inflammat Res, B-9052 Ghent, Belgium..
Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8QQ, Lanark, Scotland..
Fraunhofer Inst Translat Med & Pharmacol ITMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany..
Novartis Pharma AG, CH-4056 Basel, Switzerland..
Oxford BioDynam Ltd, Oxford OX4 2JZ, England..
SIB Swiss Inst Bioinformat, Vital IT Grp, CH-1015 Lausanne, Switzerland..
SIB Swiss Inst Bioinformat, Vital IT Grp, CH-1015 Lausanne, Switzerland..
Fraunhofer Cluster Excellence Immune Mediated Dis, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer IAIS, Inst Intelligent Anal & Informat Syst, Schloss Birlinghoven 1, D-53757 St Augustin, Germany..
Katholieke Univ Leuven, Dept Dev & Regenerat, Skeletal Biol & Engn Res Ctr, POB 813 O&N,Herestr 49, B-3000 Leuven, Belgium..
Fraunhofer Inst Translat Med & Pharmacol ITMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Theodor Stern Kai 7, D-60596 Frankfurt, Germany..
Fraunhofer Cluster Excellence Immune Mediated Dis, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer IAIS, Inst Intelligent Anal & Informat Syst, Schloss Birlinghoven 1, D-53757 St Augustin, Germany..
Fraunhofer Inst Translat Med & Pharmacol ITMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany..
Univ Coll Dublin, UCD Conway Inst, Atturos Ltd, Dublin D04 V1W8, Ireland..
Univ Glasgow, Coll Med Vet & Life Sci, Glasgow Polyom, Garscube Campus, Glasgow G61 1QH, Lanark, Scotland..
Fraunhofer Inst Translat Med & Pharmacol ITMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Inst Clin Pharmacol, Pharmazentrum Frankfurt ZAFES, Theodor Stern Kai 7, D-60590 Frankfurt, Germany..
Univ Coll Dublin, Sch Med, UCD Conway Inst, Dublin D04 V1W8, Ireland..
Fraunhofer Inst Translat Med & Pharmacol ITMP, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Fraunhofer Cluster Excellence Immune Mediated Dis, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.;Univ Hosp Frankfurt, Div Rheumatol, Theodor Stern Kai 7, D-60596 Frankfurt, Germany..
Univ Coll Dublin, UCD Conway Inst, Atturos Ltd, Dublin D04 V1W8, Ireland.;Univ Coll Dublin, Sch Med, UCD Conway Inst, Dublin D04 V1W8, Ireland..
Show others and affiliations
2022 (English)In: Biomedicines, E-ISSN 2227-9059, Vol. 10, no 10, article id 2387Article, review/survey (Refereed) Published
Abstract [en]
The definitive diagnosis and early treatment of many immune-mediated inflammatory diseases (IMIDs) is hindered by variable and overlapping clinical manifestations. Psoriatic arthritis (PsA), which develops in similar to 30% of people with psoriasis, is a key example. This mixed-pattern IMID is apparent in entheseal and synovial musculoskeletal structures, but a definitive diagnosis often can only be made by clinical experts or when an extensive progressive disease state is apparent. As with other IMIDs, the detection of multimodal molecular biomarkers offers some hope for the early diagnosis of PsA and the initiation of effective management and treatment strategies. However, specific biomarkers are not yet available for PsA. The assessment of new markers by genomic and epigenomic profiling, or the analysis of blood and synovial fluid/tissue samples using proteomics, metabolomics and lipidomics, provides hope that complex molecular biomarker profiles could be developed to diagnose PsA. Importantly, the integration of these markers with high-throughput histology, imaging and standardized clinical assessment data provides an important opportunity to develop molecular profiles that could improve the diagnosis of PsA, predict its occurrence in cohorts of individuals with psoriasis, differentiate PsA from other IMIDs, and improve therapeutic responses. In this review, we consider the technologies that are currently deployed in the EU IMI2 project HIPPOCRATES to define biomarker profiles specific for PsA and discuss the advantages of combining multi-omics data to improve the outcome of PsA patients.
Place, publisher, year, edition, pages
MDPI AG , 2022. Vol. 10, no 10, article id 2387
Keywords [en]
psoriatic diseases, psoriatic arthritis, psoriasis, multi-omics, data integration
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:kth:diva-321404DOI: 10.3390/biomedicines10102387ISI: 000872267400001PubMedID: 36289648Scopus ID: 2-s2.0-85140794576OAI: oai:DiVA.org:kth-321404DiVA, id: diva2:1710982
Note
QC 20221115
2022-11-152022-11-152022-11-15Bibliographically approved